BRISTOL MYERS SQUIBB
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
- Conditions
- Venous Thrombosis
- Interventions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5614
- Registration Number
- NCT00643201
- Locations
- ๐บ๐ธ
Pasadena Center For Medical Research, St. Petersburg, Florida, United States
๐บ๐ธGreat Falls Clinic, Llp, Great Falls, Montana, United States
๐บ๐ธInfectious Disease Of Indiana Psc, Carmel, Indiana, United States
A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: BMS-641988 (AR#2)
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 7
- Registration Number
- NCT00644488
- Locations
- ๐ฏ๐ต
Local Institution, Koto-Ku, Tokyo, Japan
Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: MDX-1342
- First Posted Date
- 2008-03-20
- Last Posted Date
- 2013-05-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 26
- Registration Number
- NCT00639834
- Locations
- ๐บ๐ธ
Impact Clinical Trials, Los Angeles, California, United States
๐บ๐ธGood Samaritan Hospital and Johns Hopkins Hospital, Baltimore, Maryland, United States
๐บ๐ธCoastal Medical Research, Inc, Port Orange, Florida, United States
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1211
- Registration Number
- NCT00636168
- Locations
- ๐บ๐ธ
Sharp Memorial Hospital, San Diego, California, United States
๐บ๐ธVanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States
๐บ๐ธThe Angeles Clinic & Research Institute, Los Angeles, California, United States
Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma
- Conditions
- Hodgkin's Lymphomas
- Interventions
- Biological: MDX-1401
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT00634452
- Locations
- ๐บ๐ธ
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
๐บ๐ธWest Virginia University, Morgantown, West Virginia, United States
๐บ๐ธClinWorks Cancer Research Center, Charlotte, North Carolina, United States
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2711
- Registration Number
- NCT00633893
- Locations
- ๐บ๐ธ
Mercury Street Medical Group, Pllc, Butte, Montana, United States
๐บ๐ธPiedmont Healthcare/Research, Statesville, North Carolina, United States
๐บ๐ธWilliam Beaumont Hospital, Royal Oak, Michigan, United States
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
- Conditions
- Advanced Non-small Cell Lung CancerPancreatic Cancer Including Ampulla of VaterTransitional Cell CarcinomaGastric/Esophageal AdenocarcinomaSoft Tissue Sarcoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 597
- Registration Number
- NCT00633789
- Locations
- ๐ฌ๐ง
Local Institution, Surrey, United Kingdom
๐บ๐ธMemorial Sloan Kettering Cancer Ctr, New York, New York, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 99
- Registration Number
- NCT00623766
- Locations
- ๐บ๐ธ
The Angeles Clinic & Research Institute, Los Angeles, California, United States
๐บ๐ธLoyola University Medical Center, Maywood, Illinois, United States
๐บ๐ธSeattle Cancer Care Alliance, Seattle, Washington, United States
Phase II, 2nd Line Melanoma - RAND Monotherapy
- Conditions
- Melanoma
- Interventions
- Drug: Anti-CD137 (4-1BB) (BMS-663513)
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 158
- Registration Number
- NCT00612664
- Locations
- ๐บ๐ธ
Blumenthal Cancer Center, Carolinas Medical Center, Charlotte, North Carolina, United States
๐บ๐ธHarry & Jeanette Weinberg Cancer Inst At Franklin Square, Baltimore, Maryland, United States
๐บ๐ธYale University School Of Medicine, New Haven, Connecticut, United States
Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 8
- Registration Number
- NCT00605618
- Locations
- ๐ฆ๐บ
Local Institution, Kogarah, New South Wales, Australia